Dermatology Devices Market Is Predicted To Reach US$ 39 Billion By 2031


According to Fact MR’s recent market research, sales of Dermatology Devices to swell at propelled CAGR through 2031, as investment towards expansion of healthcare infrastructure continues rising. The goal of the survey is uncover growth opportunities, key trends, growth drivers, and challenges. It also provides recommendations to assist businesses in preparing for unforeseen challenges.

Focus on improving overall patient care will remain a chief growth driver. Besides this, Dermatology Devices market will continue gaining from increasing willingness among patients and families to spend on advanced healthcare.

Request Sample

Key Takeaways from Market Study

  • By 2031, sales of dermatology devices are expected to bring in revenue worth US$ 39 Bn.
  • Demand is anticipated to increase at an impressive CAGR of 12.5%.
  • North America accounted for 40% of global market share in 2020.
  • The APAC market is anticipated to rise at the fastest CAGR over the next ten years.
  • Increasing awareness among consumers, rising prevalence of skin diseases and skin cancer, more investments in research, and rising disposable income are some of the factors that are expected to drive demand, globally.

“Increasing focus on aesthetics and evolving beauty standards are expected to fuel demand for dermatology devices,” says a Fact.MR analyst.

Competitive Landscape

Some of the key manufacturers of dermatology devices, such as B. Braun Melsungen AG, Erbe Elektromedizin GmbH, Heal Force Bio-meditech Holdings Limited, Johnson & Johnson Private Limited, Bovie Medical Corporation, Medtronic Plc, Smith and Nephew Co., and AngioDynamics Inc., have been profiled in this market study.

  • In August 2021, LASEROPTEK Co. Ltd., announced the launch of PALLAS Solid-State 311nm UVB in the United States. The company is known for its state-of-the-art laser devices for medical dermatology. The newly launched laser is cleared by FDA for the treatment of skin conditions such as vitiligo, psoriasis, atopic dermatitis, and leukoderma.
  • In February 2021, Pulse Biosciences Inc. did a controlled launch of its new CellFX System after successfully treating its first patients. The CellFX System is a multi-application platform based on NPS (Nano Pulse Stimulation) technology.

Leave a Reply

Related Posts